Plain-English translation of NCT05849662 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether — a targeted cancer medication — works safely when combined with (and sometimes additional chemotherapy) to treat juvenile myelomonocytic leukemia, a rare blood cancer in children and young adults. The study divides patients into two groups based on how aggressive their cancer appears: those with lower-risk disease will receive a gentler treatment plan over several months, while those with higher-risk disease will receive a more intensive treatment plan. Researchers hope this approach will help more children survive this serious illness.
Juvenile myelomonocytic leukemia is a rare and aggressive blood cancer in children that is difficult to treat with standard therapies alone. This trial exists because doctors believe that combining with other medications may be more effective and help improve survival for newly diagnosed patients.
You likely qualify if…
You likely don't qualify if…
If you have lower-risk disease, you would take the medication daily for 5 days, then continue one medication daily for a full 28-day cycle, with up to 12 cycles total over about a year. If you have higher-risk disease, you would receive a more intensive treatment with multiple medications for 5 days combined with daily medication for 28 days, with up to 2 cycles. Throughout the study, you would have regular blood tests, clinic visits, and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States